Panteli Theocharous, FIBMS, Ph.D., FRCPath, is vice president of hematology/oncology in global product development and medical strategy liaison for the commercial team.
Dr. Theocharous has devoted his life’s work to this therapeutic area, working on more than 20 hematology/oncology molecules in academic medical settings and in industry. As a stem cell transplant expert and immunologist, he has developed novel gene/cellular therapy and antibody approaches for hematological malignancies and solid tumors, and a lead allogeneic tumor cell vaccine for prostate cancer.
Prior to joining PPD, Dr. Theocharous held executive leadership roles in global clinical development, medical affairs and regulatory affairs for oncology research and development programs in the biotech and pharmaceutical industries. In addition to his clinical development leadership, he is experienced with marketing authorization applications, lifecycle management, pricing, market access and reimbursement negotiations. He has successfully delivered early, pivotal Phase II/III global registration studies, Phase IV clinical studies and patient access programs. He has forged relationships with global key opinion leaders, networks, clinical centers of excellence and cooperative groups. A recognized thought leader in oncology, he serves as the medical expert for the Leukemia Cancer Society and is an ex officio member of the International Society for Cellular Therapy (ISCT) global executive committee.
Dr. Theocharous holds a Bachelor of Science in medical biochemistry from King’s College at the University of London, a Master of Science in applied clinical hematology from the University of Westminster, and higher degrees in medicine, specializing in hematological oncology, from the Royal Free and University College Medical School at the University of London, where he was director of stem cell transplantation and cellular therapeutics.